...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Helicobacter >Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial
【24h】

Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial

机译：含有铋的四重治疗与伴随的四重治疗作为幽门螺杆菌感染幽门螺杆菌感染的一线治疗，在克拉霉素的高抗性面积：一种前瞻性，横截面，比较，开放式试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Concomitant quadruple (CQT) or bismuth-containing quadruple therapy (BQT) is recommended as first-line treatment for Helicobacter pylori infection depending on antibiotic resistance. Aim To compare the efficacy, safety, and compliance of CQT and BQT as first-line therapy for H. pylori eradication in real clinical practice in an area of high resistance to clarithromycin. Methods A prospective, open, comparative cross-sectional study including dyspeptic patients >18 years with H. pylori infection and with no previous eradication treatment was performed. CQT (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g + metronidazole 500 mg, all given twice daily, for 14 days) or BQT (omeprazole 20 mg twice daily + 3 capsules of Pylera (R) 4 times a day, for 10 days) was prescribed at the discretion of the prescribing physician. Eradication was tested by C-13-urea breath test. Efficacy was assessed by intention-to-treat (ITT) and per-protocol (PP) analyses. Results One hundred and four consecutive patients were included (64.4% female, age 52.9 years). Fifty patients received CQT and 54 BQT. Eradication rate was similar with both therapies at the PP (CQT 97.9%, 95% CI: 93.9-100 vs BQT 96.2%, 95% CI: 90.9-100, P = 0.605) and ITT analyses (CQT 98.0%, 95% CI: 94-100 vs BQT 94.4%, 95% CI: 88.1-100, P = 0.346). The rate of adverse events was also similar with CQT (56%) and BQT (46.3%). One patient in each group discontinued the treatment due to significant adverse events. Conclusion The use of CQT and BQT as first-line treatment against H. pylori is similarly effective and safe strategy in an area of high clarithromycin resistance.
机译：背景技术伴随的四肢（CQT）或含有铋的四重治疗（BQT）被推荐为幽门螺杆菌感染的一线治疗，这取决于抗生素抗性。旨在比较CQT和BQT的疗效，安全性和依从性作为H.幽门螺杆菌的一线治疗在高抗胰岛素的高抗性区域中的真正临床实践中的临床实践。方法对幽门螺杆菌感染和未经先前的根除治疗，术后预期，开放，比较横截面研究> 18岁。 CQT（Omeprazole 20mg + Clarithromycin 500 mg + Amoxicillin 1 G +甲硝唑500mg，每天给予两次，14天）或BQT（Omeprazole 20 mg每日两次+ 3胶囊（r）每天4次4次，10次天）由处方医师自行决定进行。通过C-13-urea呼气测试测试了根除。通过意向治疗（ITT）和每方案（PP）分析评估疗效。结果包括一百四个连续患者（女性64.4％，52.9岁）。五十名患者接受CQT和54 BQT。消除率与PP的两种疗法相似（CQT 97.9％，95％CI：93.9-100 VS BQT 96.2％，95％CI：90.9-100，P = 0.605）和ITT分析（CQT 98.0％，95％CI ：94-100 VS BQT 94.4％，95％CI：88.1-100，P = 0.346）。不良事件的速率也与CQT（56％）和BQT（46.3％）类似。每组的一名患者由于显着不良事件而停止治疗。结论CQT和BQT的使用作为针对H.Pylori的一线治疗在高克拉霉素抵抗力面积中是类似的有效和安全的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号